Highlights SeaStar Medical Holding Corporation

Equities

ICU

US81256L1044

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
0.3863 ^USD	-3.91%		-4.14%	-12.74%

04-30	SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure	CI
04-16	SeaStar Medical Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SeaStar Medical Holding Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	04-16	CI
Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients	03-12	CI
SeaStar Medical Shares Rise 10% After FDA Humanitarian Device Exemption Approval	02-22	DJ
FDA Grants Humanitarian Device Exemption Approval to Seastar Medical?S Selective Cytopheretic Device for Pediatric Acute Kidney Injury	02-22	CI
SeaStar Medical Gets Canadian Patent Covering Technology for Cell-Directed Therapy	02-01	MT
SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury	12-28	CI
SeaStar Medical Holding Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients	30/10/23	CI
FDA Grants SeaStar Medical?s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome	18/10/23	CI
Seastar Medical Holding Corporation Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption	03/10/23	CI
SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device	29/08/23	CI
SeaStar Medical Holding Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury	20/06/23	CI
SeaStar Medical Holding Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device	09/05/23	CI
SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury	15/02/23	CI
Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury	09/02/23	CI
SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients	09/01/23	CI
SeaStar Medical Ties Up With Nuwellis for Marketing of Treatment Device for Acute Kidney Injury in Children	29/12/22	MT
SeaStar Medical Holding Corporation and Nuwellis, Inc. Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury	29/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SeaStar Medical Holding Corporation

Equities

ICU

US81256L1044

Highlights

Filters